Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $100.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective raised by investment analysts at Stephens from $95.00 to $100.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Stephens’ target price suggests a potential upside of 13.42% from the company’s previous close.

Other equities analysts have also issued reports about the stock. Wells Fargo & Company boosted their price objective on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. Mizuho raised their target price on Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Barclays upped their target price on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a report on Tuesday, January 27th. Finally, Oppenheimer upped their price target on Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $117.10.

Kymera Therapeutics Stock Down 3.5%

Shares of KYMR opened at $88.17 on Monday. The stock has a market cap of $7.20 billion, a P/E ratio of -23.97 and a beta of 2.20. The business’s 50 day moving average price is $78.52 and its 200-day moving average price is $65.62. Kymera Therapeutics has a 52 week low of $19.44 and a 52 week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the previous year, the firm posted ($0.88) EPS. The firm’s quarterly revenue was down 60.8% compared to the same quarter last year. On average, equities analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Activity

In other news, Director Bros. Advisors Lp Baker purchased 2,005,813 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average cost of $86.00 per share, for a total transaction of $172,499,918.00. Following the acquisition, the director owned 7,955,916 shares of the company’s stock, valued at approximately $684,208,776. This trade represents a 33.71% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jared Gollob sold 49,307 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $88.67, for a total value of $4,372,051.69. Following the completion of the sale, the insider owned 109,992 shares in the company, valued at approximately $9,752,990.64. The trade was a 30.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 450,895 shares of company stock worth $40,486,151 in the last 90 days. Company insiders own 16.01% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its holdings in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the period. Smartleaf Asset Management LLC lifted its stake in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC grew its holdings in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares in the last quarter. Osaic Holdings Inc. raised its holdings in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares in the last quarter. Finally, Bessemer Group Inc. lifted its position in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.